Estrogen receptor-positive (ER + ) breast cancer is the most common breast cancer subtype.
Treatment of ER + breast cancer comprises interventions that suppress estrogen production …

Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib
plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ …

We present an oblique plane microscope (OPM) that uses a bespoke glass-tipped tertiary
objective to improve the resolution, field of view, and usability over previous variants. Owing to …

Human epidermal growth factor receptor 2 (HER2; ERBB2) amplification and
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations often …

Detection of minor, genetically distinct subpopulations within tumors is a key challenge in
cancer genomics. Here we report STAR-FISH (specific-to-allele PCR–FISH), a novel method …

Despite the modest clinical activity of PI3K inhibitors in solid tumors, there is an increasing
understanding of the factors that may have limited their success. Strategies to ameliorate drug-…

Disseminated tumor cells with metabolic flexibility to utilize available nutrients in distal organs
persist, but the precise mechanisms that facilitate metabolic adaptations remain unclear. …

The ERBB family of receptor tyrosine kinases has been implicated in carcinogenesis for over
three decades with rigorous attention to EGFR and HER2. ERBB receptors, consisting of …

HER2+ breast cancer patients are presented with either synchronous (S-BM), latent (Lat), or
metachronous (M-BM) brain metastases. However, the basis for disparate metastatic fitness …

We report a HER2 T798I gatekeeper mutation in a patient with HER2 L869R -mutant breast
cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2 …